The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2024 | Assessing the value of various prognostic biomarkers in AL amyloidosis
Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, discusses traditional and novel biomarkers for prognostication in light chain (AL) amyloidosis. Whilst traditional factors such as cardiac biomarkers (troponin T, NT-proBNP) are great prognostic tools, newer factors such as the global longitudinal strain (GLS) and 6-minute walking distance (6MWD) also have prognostic value. Dr Khwaja highlights research assessing the value of these biomarkers in patients between 2010 and 2019, and further comments on how staging in AL amyloidosis may change in the future. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
